Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336


Baseline Characteristics of Patients by Sex


Changes in LDL and hs-CRP levels in women and men as stratified by randomization treatment group from baseline to final visit

Q.A. Truong et al. CCQO 2011;4:328-336

Percentage of patients with achieved LDL and hs-CRP target levels

Percentage of patients with achieved LDL target levels of 100 mg/dL and 70 mg/dL (A) and with achieved hs-CRP 2 mg/LLDL 70 mg/dL (B) by randomized treatment group as stratified by sex at 30 days and at the final visit. A, All P<0.001 when comparing proportion of patients with achieved target LDL levels with atorvastatin versus pravastatin as stratified by women and men. A greater proportion of men reached target LDL levels with atorvastatin than did women (all P<0.001). In patients receiving pravastatin, the proportion of men and women who achieved target LDL levels was not different (all P<0.13).B, All P<0.015 when comparing proportions of patients with achieved hs-CRPLDL levels with treatment group as stratified by sex.


Rate of Premature Discontinuation of Statin Therapy and Side Effects of High- Versus Standard-Dose

Statin as Stratified by Sex


Kaplan-Meier curves of primary end point by study termination in women (A) and men (B)


Hazard ratios between intensive-dose atorvastatin and standard-dose pravastatin therapy in women and men


Hazard ratios of the primary end point in women treated with intensive lipid-lowering therapy

(atorvastatin 80 mg) compared to standard lipid-lowering therapy (pravastatin 40 mg) therapy


WHAT THE STUDY ADDS

Documents

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336